Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 480
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Matthew Craig Kapusta | CEO & Executive Director | 1,02M | N/D | 1972 |
Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 575,46k | N/D | 1973 |
Mr. Pierre Caloz | Chief Operating Officer | 882,59k | N/D | 1973 |
Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | 732,17k | N/D | 1968 |
Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | 635,56k | N/D | 1962 |
Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | N/D | N/D | N/D |
Dr. Tamara Tugal Ph.D., MBA | Business Development Director | N/D | N/D | N/D |
Ms. Carla Poulson | Interim Chief People and Culture Officer | N/D | N/D | N/D |
Ms. Maria E. Cantor | Chief Corporate Affairs Officer | 491,12k | N/D | 1968 |
Dr. Amin Abujoub Ph.D. | Chief Quality Officer | N/D | N/D | N/D |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
L'ISS Governance QualityScore di uniQure N.V. al 1 maggio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 5.